| __timestamp | Biogen Inc. | Dynavax Technologies Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 2232342000 | 17763000 |
| Thursday, January 1, 2015 | 2113100000 | 22180000 |
| Friday, January 1, 2016 | 1947900000 | 37257000 |
| Sunday, January 1, 2017 | 1935500000 | 27367000 |
| Monday, January 1, 2018 | 2106300000 | 64770000 |
| Tuesday, January 1, 2019 | 2374700000 | 74986000 |
| Wednesday, January 1, 2020 | 2504500000 | 79256000 |
| Friday, January 1, 2021 | 2674300000 | 100156000 |
| Saturday, January 1, 2022 | 2403600000 | 131408000 |
| Sunday, January 1, 2023 | 2549700000 | 152946000 |
| Monday, January 1, 2024 | 2403700000 |
Infusing magic into the data realm
In the ever-evolving world of biotechnology, understanding the financial dynamics of industry leaders is crucial. Biogen Inc. and Dynavax Technologies Corporation, two prominent players, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Biogen's SG&A costs have consistently been over 30 times higher than those of Dynavax, reflecting its expansive operations and market reach. Notably, Biogen's expenses peaked in 2021, marking a 38% increase from 2014, while Dynavax saw a staggering 760% rise in the same period, albeit from a much smaller base. This disparity highlights Biogen's established market presence and Dynavax's aggressive growth strategy. As the biotech sector continues to innovate, these financial insights offer a glimpse into the strategic priorities of these industry titans.
Selling, General, and Administrative Costs: Johnson & Johnson vs Dynavax Technologies Corporation
Breaking Down SG&A Expenses: AstraZeneca PLC vs Biogen Inc.
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Biogen Inc.
Selling, General, and Administrative Costs: argenx SE vs Biogen Inc.
Cost Management Insights: SG&A Expenses for Biogen Inc. and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Biogen Inc. vs Wave Life Sciences Ltd.
SG&A Efficiency Analysis: Comparing Biogen Inc. and Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Dynavax Technologies Corporation
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: ImmunityBio, Inc. vs Dynavax Technologies Corporation
Soleno Therapeutics, Inc. vs Dynavax Technologies Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Dynavax Technologies Corporation and Travere Therapeutics, Inc.